Hepatitis B Trial, Recruiting (NCT05051098)

Hepatitis B Trial, Recruiting NCT05051098 Sponsor: Hannover Medical School Condition: Hepatitis B

Printed from Voxsanity (voxsanity.com.au) — NCT05051098 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hepatitis B

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a Hepatitis B virus infection
You have tested positive for a specific Hepatitis B marker (called HBsAg) for at least 1 year before joining the trial
Your Hepatitis B "e-antigen" (HBeAg) status has been monitored and documented for at least 6 months (confirm with trial site)

Who may not be able to join:

You are over 70 years old
You also have HIV or an active Hepatitis C infection
You have another significant liver condition alongside Hepatitis B, such as alcohol-related liver disease, fatty liver disease, an autoimmune liver condition, or certain inherited liver disorders (confirm with trial site for the full list)
You have another serious ongoing illness, such as cancer
You are taking a high dose of steroid-based medication (above a certain threshold set by the trial team)
You have liver cirrhosis (scarring of the liver), whether diagnosed by a doctor or detected by scan or special imaging
You have a history of liver cancer (hepatocellular carcinoma)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Markus Cornberg, Hannover Medical School

Phone: +49511532

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05051098

Sponsor: Hannover Medical School

Phase: Not Applicable

Status: Recruiting

Condition: Hepatitis B

Trial contact: +49511532

More information: https://clinicaltrials.gov/study/NCT05051098

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a Hepatitis B virus infection
You have tested positive for a specific Hepatitis B marker (called HBsAg) for at least 1 year before joining the trial
Your Hepatitis B "e-antigen" (HBeAg) status has been monitored and documented for at least 6 months (confirm with trial site)

Who may not be able to join:

You are over 70 years old
You also have HIV or an active Hepatitis C infection
You have another significant liver condition alongside Hepatitis B, such as alcohol-related liver disease, fatty liver disease, an autoimmune liver condition, or certain inherited liver disorders (confirm with trial site for the full list)
You have another serious ongoing illness, such as cancer
You are taking a high dose of steroid-based medication (above a certain threshold set by the trial team)
You have liver cirrhosis (scarring of the liver), whether diagnosed by a doctor or detected by scan or special imaging
You have a history of liver cancer (hepatocellular carcinoma)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Hannover Medical School

Registry

ClinicalTrials.gov

Start date

6 May 2021

Est. completion

1 December 2025

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Number of patients with change HBsAg levels; Number of patients with seroconversion to anti-HBs; Quantification of IL6, IP-10, IFNg and IL1beta and correlation with HBsAg and ALT levels

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov